Combining oncolytic viruses and small molecule therapeutics: Mutual benefits

13Citations
Citations of this article
36Readers
Mendeley users who have this article in their library.

Abstract

The focus of treating cancer with oncolytic viruses (OVs) has increasingly shifted towards achieving efficacy through the induction and augmentation of an antitumor immune response. However, innate antiviral responses can limit the activity of many OVs within the tumor and several immunosuppressive factors can hamper any subsequent antitumor immune responses. In recent decades, numerous small molecule compounds that either inhibit the immunosuppressive features of tumor cells or antagonize antiviral immunity have been developed and tested for. Here we comprehensively review small molecule compounds that can achieve therapeutic synergy with OVs. We also elaborate on the mechanisms by which these treatments elicit anti-tumor effects as monotherapies and how these complement OV treatment.

Cite

CITATION STYLE

APA

Spiesschaert, B., Angerer, K., Park, J., & Wollmann, G. (2021, July 2). Combining oncolytic viruses and small molecule therapeutics: Mutual benefits. Cancers. MDPI. https://doi.org/10.3390/cancers13143386

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free